Why carry out this study?

Guselkumab, a fully human monoclonal antibody that binds to the p19 subunit of interleukin-23, has shown improvement of clinical disease outcomes and patient-reported outcome measures (PROMs) and has an established safety profile in moderate-to-severe psoriasis.

Although clinical trials have typically focused on specific criteria for moderate-to-severe psoriasis, patient populations receiving guselkumab in the real world may reflect all Investigator’s Global Assessment (IGA) severities of the disease; limited information is available regarding outcomes after guselkumab therapy in typical clinical practice in the USA and Canada.

The objective of this study was to assess the effectiveness of 9–12 months of persistent guselkumab therapy among US and Canadian patients with plaque psoriasis and a baseline IGA score ≥2 (mild or greater disease severity) who initiated treatment in the CorEvitas Psoriasis Registry.

What was learned from this study?

At follow-up, guselkumab-treated patients showed reductions in the severity of their disease; furthermore, all mean changes in disease activity and PROMs showed improvement, with all differing significantly from zero except for the percentage of work hours missed because of psoriasis.

To our knowledge, this is the first real-world study to evaluate outcomes among patients with mild, moderate, and severe IGA severities of psoriasis who received guselkumab therapy in the USA and Canada; although longer follow-up is warranted, the results show that treatment can provide improvement of mild-to-severe disease in typical clinical practice.